Cutera (NASDAQ:CUTR) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Cutera (NASDAQ:CUTR) in a research report sent to investors on Monday morning. The brokerage issued a sell rating on the medical device company’s stock.

A number of other equities research analysts also recently issued reports on CUTR. Piper Sandler reissued a “neutral” rating and set a $1.00 price objective (down previously from $3.00) on shares of Cutera in a research report on Friday, August 9th. Stephens cut their price target on Cutera from $10.00 to $5.00 and set an “overweight” rating for the company in a report on Friday, August 9th.

Cutera Price Performance

NASDAQ CUTR opened at $0.31 on Monday. The firm has a market capitalization of $6.18 million, a P/E ratio of -0.05 and a beta of 1.35. The company has a 50-day moving average price of $0.63 and a 200-day moving average price of $1.20. Cutera has a 52 week low of $0.28 and a 52 week high of $4.97.

Institutional Trading of Cutera

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Squarepoint Ops LLC boosted its holdings in Cutera by 164.5% in the 2nd quarter. Squarepoint Ops LLC now owns 113,964 shares of the medical device company’s stock worth $172,000 after buying an additional 70,870 shares during the period. Bank of Montreal Can boosted its stake in shares of Cutera by 14.2% in the second quarter. Bank of Montreal Can now owns 282,704 shares of the medical device company’s stock worth $455,000 after acquiring an additional 35,248 shares during the period. Ground Swell Capital LLC purchased a new stake in shares of Cutera during the second quarter worth about $37,000. Bayesian Capital Management LP bought a new stake in Cutera during the 1st quarter valued at approximately $33,000. Finally, BNP Paribas Financial Markets lifted its holdings in Cutera by 7.1% in the 1st quarter. BNP Paribas Financial Markets now owns 75,833 shares of the medical device company’s stock worth $111,000 after purchasing an additional 5,017 shares in the last quarter. 90.70% of the stock is owned by hedge funds and other institutional investors.

Cutera Company Profile

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform.